一般社団法人日本呼吸器学会 公式サイト
日本呼吸器学会英文誌 Respiratory Investigation
日本呼吸器学会誌 増刊号 学術講演会プログラム 抄録集 検索用
日本呼吸器学会誌 増刊号 学術講演会プログラム 抄録集 全文PDF

Abstract

Full Text of PDF Full Text of PDF (627k)
Article in Japanese

Original Article

Effectiveness of liver hydrolysate composite (Proheparum®) on hepatotoxicity of gefitinib therapy in nonsmall cell lung cancer patients

Ryo Itotani  Masaya Takemura  Daiki Inoue  Kazufumi Takamatsu  Manabu Isitoko  Shinko Suzuki  Masataka Matsumoto  Minoru Sakuramoto  Motonari Fukui 

Respiratory Disease Center, Kitano Hospital, Tazuke Kofukai Medical Research Institute

ABSTRACT

The chemotherapy of nonsmall cell lung cancer is making brilliant progress by introducing gefitinib, an oral tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR). Although the hepatotoxicity has often been encountered with gefitinib therapy, no standard remedies for this side effect are available. Our aim is to clarify the efficacy of Proheparum®, a liver hydrolysate composite used to treat chronic hepatic diseases, on the hepatotoxicity resulting from gefitinib therapy. From November 2007 to May 2010, we reviewed patients with nonsmall cell lung cancer and identified 10 patients who developed Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 Grade 1 or more hepatotoxicity after the initiation of gefitinib therapy, followed by receiving Proheparum®. The clinical effects of Proheparum® were retrospectively investigated. Decreased serum alanine aminotransferase (ALT) levels were recognized in 8 of 10 patients, and decreased serum asparatate aminotransferase (AST) levels were recognized in 7 of 10 patients after the initiation of Proheparum®. Among these 8 patients, 3 improved and showed decreased levels of serum ALT levels without interruptions or dose reductions of gefitinib administration. The remaining 5 patients were given Proheparum® concomitant with dose reductions or interruptions of gefitinib, and/or administration of Stronger Neo-minophagen C® (SNMC), a glycyrrhizin preparation. Three of these 5 patients were successfully readministered gefitinib together with Proheparum® without relapse of hepatotoxicity. In conclusion, Proheparum® may be effective for nonsmall lung cancer patients with hepatotoxicity as a result of gefitinib therapy.

KEYWORDS

Gefitinib  Proheparum®  Liver hydrolysate composite  Hepatotoxicity  Non-small cell lung cancer 

Received 28 Jul 2011 / Accepted 14 Feb 2012

AJRS, 1(5): 369-373, 2012

Google Scholar